Lens On Digital Health / AI Startup: Crely

Crely.AI: Revolutionizing Post Operative Care for Osteoarthritis Patients via AI

According to the Centers for Disease Control and Prevention (CDC), arthritis affects 23% of adults in the US, or 54 million people, and is expected to rise to 78 million cases by 2040. The annual direct medical costs are at least 81 billion. Anyone who injures or overuses their joints, including athletes, military members, and people who work physically demanding jobs, may be more susceptible to developing this disease as they age. The most common type of arthritis is Osteoarthritis (OA). OA is a chronic condition that can affect any joint, but it occurs most often in knees, hips, lower back and neck, small joints of the fingers and the bases of the thumb and big toe.

(Arthritis Foundation)

(Arthritis Foundation)

Crely is an innovative digital health platform that uses proprietary wearable sensor data and deep learning algorithms to improve health outcomes for hip and knee osteoarthritis patients after the surgery. Founded by a veteran in the medical technology space and Harvard Business School alumni, Arun Sethuraman, Crely has identified an under-served segment in the orthopedic space that sees significant cost escalations due to poor post operative care and negligence.

According to Crely, "For hospitals and accountable care organizations who must manage post-discharge costs for Total Knee Arthroplasty (TKA) and Total Hip Arthroplasty (THA) patients, including cost of re-admissions during the 90 day clinical episode, Crely is a new service to minimize post-acute care (PAC) costs, while not compromising patient clinical outcomes."

The company is at the Proof of Concept stage and poised to ensure this niche medical space moves towards value based care via its AI technology.

Even though the commercialization of the company’s technology rests on the success of the various clinical studies that it is conducting, and there are a few other players as well that are eyeing this lucrative segment, Crely’s unique approach to solve the problem in the osteoarthritis space stands out among its peers.